RxDoctor Payments Data

Sarah Hill

Anatomic Pathology · Boston, MANPI 1912357138

Payments from drug & device makers

What this record shows

This record is dominated by grants: $54,000 of the $54,394 with a category attached, or 99.3%. AstraZeneca accounts for 99.3% of it on its own, with 1 other manufacturer making up the rest. Among anatomic pathology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$54,394in general payments, 2019–2025

Across 2 payments — averaging $27,197 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$54K
  • Eli Lilly$394
$1,006,776in research payments, 2019–2025

Across 8 payments — averaging $125,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$533K
  • Merck$380K
  • Astrazeneca UK Limited$93K

What the payments were for

  • Grants$54,00099%
  • Travel & lodging$3941%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$54,000
Eli Lilly1$394

How this compares

$54,394 in reported general payments places this provider in the 95th percentile of 119 anatomic pathology providers in Massachusetts.

See all anatomic pathology providers in Massachusetts →

Other anatomic pathology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →